Abstract: A method for reconstructing a three-dimensional model of point clouds includes following steps: a, scanning to obtain point clouds of an object required for a three-dimensional modelreconstruction; b, analyzing quality of the obtained point clouds; c, computing a new scanning view based on the analyzed point clouds; d, scanning according to the new scanning view and updating the point clouds of step a based on point clouds obtained by the scanning according to the new scanning view in real time; and e, reconstructing a three-dimensional model according to the point clouds updated in real time. The invention further relates to a system for reconstructing a three-dimensional model of point clouds. The invention can realize full automatic reconstruction of a three-dimensional model and create a model of point clouds with high quality. In addition, the invention is easy to implement and can achieve high efficiency.

Abstract: The present invention relates to compositions and methods for the treatment of diabetic neuropathies. More particularly, this invention relates to compositions and methods for promoting nerve regeneration in a subject suffering from, or at risk of suffering from a diabetic neuropathy, and for protecting nervous system cells against the stresses resulting from the perturbation of glucose homeostasis. More specifically, the present invention relates to novel single or combination therapies for diabetic neuropathies, comprising diabetic peripheral neuropathy, diabetic proximal neuropathy, diabetic autonomic neuropathy and diabetic focal neuropathy, based on restoring dorsal root ganglion neurons and other nerves integrity.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Abstract: The present invention relates to combinations and methods for the treatment of macular degeneration disorders. More specifically, the present invention relates to novel combinatorial therapies of Age related Macular Degeneration based on baclofen and acamprosate combination.

Abstract: A method for depth mapping includes projecting a pattern of optical radiation onto an object. A first image of the pattern on the object is captured using a first image sensor, and this image is processed to generate pattern-based depth data with respect to the object. A second image of the object is captured using a second image sensor, and the second image is processed together with another image to generate stereoscopic depth data with respect to the object. The pattern-based depth data is combined with the stereoscopic depth data to create a depth map of the object.

Abstract: The present disclosure provides a computer implemented method of image processing comprising, upon receiving of first and second images from an imaging unit, the first and second images being respectively associated with first and second rotational changes between a reference orientation and the orientations of the first and second images: processing data representative of the first image and of the second image to compensate the first and second rotational changes between the reference orientation and the respective orientations of the first and second images, thereby obtaining first and second corrected images; processing the first corrected image to detect distinctive keypoints within a fronto-parallel strip of the first corrected image; searching keypoints in the second corrected image corresponding to the detected keypoints, and estimating a geometric transformation between the first and second images based on matching the keypoints in the first and the second corrected images.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death and/or glucose impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Abstract: The present invention relates to development, validation and application of new sets of biomarkers for diagnosis of Alzheimer's disease (AD) and related disorders including early diagnosis of MCI and early prodrome of AD, identification of disease sub types, prediction of their response to disease management procedures, drugs and their combinations and for monitoring response for these treatments, including validation of biomarkers for clinical trials.

Abstract: A system, method and computer program product for scalable, rule-based processing, including an automaton builder for constructing automatons corresponding to trigger rules and word lists that are employed by the trigger rules, and a rule evaluator for evaluating any of the trigger rules with respect to an input document by selecting any of the automatons to evaluate a given one of the trigger rules, parsing the input document using the selected automatons, determining whether conditions of the given trigger rule are met, and identifying any actions that are associated with the given trigger rule.

Abstract: The present invention relates in particular to methods of detecting predisposition to or diagnosis and/or prognosis of Charcot-Marie-Tooth (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers, which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes, assessing the responsiveness to the treatments and the efficacy of treatments in subjects having CMT or a related disorder.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.

Abstract: The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder.

Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.